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Abstract 8 
The ideal scaffold for bone regeneration is required to be highly porous, non-immunogenic, biostable until 9 
the new tissue formation, bioresorbable and osteoconductive. This study aimed at investigating the process 10 
of new bone formation in patients treated with granular SmartBone® for sinus augmentation, providing an 11 
extensive histologic analysis. Five biopsies were collected at 4-9 months post SmartBone® implantation and 12 
processed for histochemistry and immunohistochemistry. Histomorphometric analysis was performed. 13 
Bone-particle conductivity index (BPCi) was used to assess SmartBone® osteoconductivity.  14 
At 4 months, SmartBone® (12%) and new bone (43.9%) were both present and surrounded by vascularized 15 
connective tissue (37.2%). New bone was grown on SmartBone® (BPCi = 0.22). At 6 months, SmartBone® 16 
was almost completely resorbed (0.5%) and new bone was massively present (80.8%). At 7 and 9 months, 17 
new bone accounted for a large volume fraction (79.3% and 67.4%, respectively) and SmartBone® was 18 
resorbed (0.5% and 0%, respectively). Well-oriented lamellae and bone scars, typical of mature bone, were 19 
observed. In all the biopsies, bone matrix biomolecules and active osteoblasts were visible. The absence of 20 
inflammatory cells confirmed SmartBone® biocompatibility and non-immunogenicity. These data indicate 21 
that SmartBone® is osteoconductive, promotes fast bone regeneration, leading to mature bone formation 22 
in about 7 months.  23 
 24 
  25 
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1. Introduction 1 
 2 
In bone tissue engineering, an ideal scaffold is asked for several key requirements, which must also take 3 
into account its specific body location and physiologic tasks. Some requirements are broadly considered 4 
fundamental in any osseous reconstruction: namely, non-immunogenicity, sufficient biostability until the 5 
formation of mature bone, and high porosity for cell migration, extracellular matrix (ECM) deposition and 6 
vascularization (Bose et al., 2012). In addition, the optimal scaffold for bone regeneration should be 7 
bioresorbable to permit its substitution with newly formed bone, osteoconductive to attract resident 8 
osteoblasts to build new bone, and possibly osteoinductive to induce the osteogenic differentiation of 9 
mesenchymal stromal cells (Bose et al., 2012). Every year, over 2 million bone-grafting procedures are 10 
performed worldwide for orthopedic treatments, and even more for dental surgery, so that the search for 11 
the ideal bone substitute has become more and more specifically tailored to the final application.  12 
Maxillary sinus augmentation is a routinely surgical procedure of bone reconstruction and consolidation by 13 
means of grafting materials, which has reached a 90% success rate of dental implant in the mid-term (3-5 14 
years) (Del Fabbro et al., 2004). So far, the autologous bone, often taken from the iliac crest, is considered 15 
the gold standard material for bone replacement for its osteoconductive and osteoinductive properties 16 
(Burchardt, 1983; van den Bergh et al., 1998; Jensen at al., 1998; Klijn et al., 2010). However, autografting 17 
procedures are constrained by some important disadvantages, such as extended surgical time and costs, 18 
pain associated to morbidity, resorption unpredictability and limited tissue availability (Burchardt, 1983; 19 
Burchardt, 1987; Raghoebar et al., 2001; Klijn et al., 2010). For these reasons, ongoing research efforts are 20 
investigating the performance of other biomaterials to be used as bone substitutes in dental surgery.  21 
Among synthetic materials, bioactive glasses, resorbable hydroxyapatite (HA), β-tricalcium phosphate (TCP) 22 
and their combinations have been proposed for their similarity to the osseous mineral matrix (Wagner, 23 
1991; Tadjoedin et al., 2000; Artzi et al., 2005; Frenken et al., 2010). Resorbable calcium phosphates own 24 
osteoconductive properties and, according to their resorption rates, are progressively substituted by new 25 
bone. These materials differ from bone grafts as they do not possess ECM organic molecules, the latter 26 
playing a dual role of providing both the structural support for the mineral phase and the stimulatory cues 27 
for the resident cells to promote graft remodeling and new bone formation (Simunek et al, 2008). On the 28 
other hand, although similar in composition and structure to bone ECM, homo- and xeno-grafts carry the 29 
risk of inflammatory and foreign body reactions, and for these reasons they are usually processed to lose 30 
their immunogenic properties (Graham et al., 2010).  31 
Among tissue grafts, banked bone from donors represents an interesting alternative to autografts, but 32 
ethical constraints, issues on costs, safety and availability have limited its use in oral surgery (van den Bergh 33 
et al., 2000; Froum et al., 2006). Therefore, bovine deproteinized (anorganic) bone matrix has become a 34 
very popular grafting material for the maxillary floor augmentation owing to its large availability and 35 
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reduced costs (Piattelli et al., 1999; Tadjoedin et al., 2003). In such a variegated biomaterials scenario, in 1 
which new grafts and their combinations with synthetic biomaterials are proposed as scaffolds for sinus lift 2 
procedures, the best clinical choice may be challenging.  3 
A review study conducted in 2009 has reported a 16-year meta-analysis of the English literature about the 4 
performance of biomaterials used for sinus floor augmentation (Klijn et al., 2010). This meta-analysis 5 
showed that the autologous bone grafting scored the highest total bone volume, thus corroborating to be 6 
the gold standard material in sinus lift applications. However, when autologous bone is used for grafting, it 7 
is impossible to distinguish between the areas of newly formed and transplanted bone in the tissue 8 
biopsies. For this reason, the authors refer to “total bone volume”, which is, for autografts, an overestimate 9 
of the newly formed bone. Differently, when processed bone grafts and other biomaterials are used, only 10 
the new bone is measured (Klijn et al., 2010). This measurement uncertainty is suggestive that other well 11 
preforming materials, such as deproteinized bovine bone matrix, could be improved and therefore could 12 
move close to the performance of autologous bone. A recent meta-analysis and review study has indeed 13 
highlighted that bovine bone grafts and TCP/HA mixtures could be considered second choice substitutes to 14 
autologous bone grafting, concluding that comparative histologic studies are still necessary (Corbella et al., 15 
2015).  16 
In addition to the performance uncertainty of the current grafts, extensive histological analyses aimed at 17 
disclosing the processes and timeline of new bone formation and graft resorption are not present in 18 
literature. Among modified xenografts, a scaffold composed of processed bovine bone matrix reinforced 19 
with biopolymers and active agents has recently been proposed as bone substitute for oral surgery, 20 
maxillofacial and dental implantology, and is available as a new CE-labeled class III medical device 21 
(SmartBone®) (Pertici, 2010). This hybrid material is entitled to have excellent mechanical and bone 22 
regeneration properties, proposing to be a great promise for dental and maxillofacial bone tissue 23 
engineering (Pertici et al., 2014; Pertici et al., 2015). 24 
This study aimed at performing an extensive histological investigation to assess the biologic processes 25 
leading to new bone formation in 5 patients treated with granular SmartBone® for sinus floor 26 
augmentation. Histological, immunohistochemical and histormorphometrical analyses, including an 27 
osteoconductivity index, were carried out at different times post SmartBone® implantation to assess the 28 
quality and quantity of newly formed bone, and to study the process of interaction between this scaffold 29 
and the maxillary bone microenvironment. New knowledge on these phenomena could foster the 30 
development of advanced scaffolds able to regenerate new bone, which may ultimately provide for the 31 
unmet needs in dental and maxillofacial surgery. 32 
 33 
  34 
2. Materials and Methods 35 
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 1 
2.1 Sample collection  2 
Biopsies were collected from 5 patients who underwent sinus lift procedure with granular SmartBone® 3 
(Industrie Biomediche Insubri S/A, Mezzovico-Vira, Switzerland) prior to dental implant placement. 4 
SmartBone® was applied by dental surgeons following the instruction for use, as reported by the 5 
manufacturer. Bone samples, routinely removed to create a pilot hole for further implant insertion, were 6 
used for this study. These samples were cut with a trephine burr and collected at different time points post 7 
SmartBone® implantation, namely 4, 4, 6, 7 and 9 months. 8 
 9 
2.2 Sample preparation 10 
Cylinder-like specimens with diameters ranging in 2.0-2.5 mm and lengths up to 6 mm, and plain 11 
SmartBone® as control, were fixed in 10% neutral buffered formalin containing 4% formaldehyde w/v (Bio- 12 
Optica, Milan, Italy) overnight at 4°C, washed in 1× phosphate-buffered saline (1× PBS) and decalcified in a 13 
double distilled water (dd-H2O) solution of 10% ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich, St. 14 
Louis, MO, USA) at 4°C for 14 days, replacing the solution every 3-4 days. After the decalcification 15 
procedure was over, the specimens were dehydrated through immersion in a graded series of ethanol 16 
(Sigma-Aldrich)/water (v/v%) solutions: namely, in 70% ethanol for 30 min, in 80% ethanol for 30 min, in 17 
95% ethanol twice, each for 45 min, up into absolute ethanol 3 times, each for 1 h, and finally clarified in 18 
xylene (Sigma-Aldrich) twice for 45 min, performing all the steps inside a thermostatic bath set at 40°C. 19 
Thereafter, the samples were rinsed in liquid paraffin pre-warmed at 60°C and finally paraffin-embedded. 20 
Tissue sections, 6 μm thick were obtained with a standard rotating microtome, mounted on glass slides and 21 
stored at 37°C.  22 
Before each staining or reaction, the sections were deparaffinized by soaking them in xylene twice, each for 23 
7 min, and rehydrated in absolute ethanol 3 times, each for 7 min. All these steps were performed at room 24 
temperature (RT). 25 
 26 
2.3 Histochemical analyses 27 
Histochemical analyses were performed using the following staining and reaction protocols. After each 28 
staining or reaction was performed, the samples were dehydrated in absolute ethanol (3 rinses, 5 min 29 
each), clarified in xylene (3 rinses, 5 min each) and finally mounted using DPX (Sigma-Aldrich) as a mounting 30 
medium. All the steps were performed at RT. 31 
 32 
2.3.1 Hematoxylin and Eosin (H&E) staining 33 
H&E was used to highlight cell and tissue morphology. The sections were incubated in hematoxylin solution 34 
(Sigma-Aldrich) for 5 min and washed in tap water for 5 min to reveal the staining. The samples were 35 
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subsequently incubated in eosin solution (Sigma-Aldrich) for 1 min, quickly rinsed in dd-H2O and 1 
dehydrated as described in section 2.3. All the steps were performed at RT. 2 
 3 
2.3.2 Periodic Acid Schiff (PAS) reaction 4 
PAS reaction reveals the glycoproteins in magenta. The sections were incubated in periodic acid (Sigma-5 
Aldrich) diluted to 1% w/v in dd-H2O for 10 min and. Thereafter, the solution was removed and the sections 6 
air dried. Dried sections were incubated in Schiff reagent solution (Sigma-Aldrich) for 15 min. Subsequently, 7 
the samples were counterstained in hematoxylin solution for 5 min and washed in tap water for 5 min to 8 
reveal the counterstaining. All the steps were performed at RT. 9 
 10 
2.3.3 Alcian Blue staining 11 
Alcian Blue staining at pH 2.5 highlights generic glycosaminoglycans (GAGs) in cyan. The sections were 12 
incubated in Alcian Blue solutions (kit 04-161802, Bio-Optica, Milan, Italy), according to manufacturer’s 13 
instructions. Briefly,  the sections were incubated in Alcian Blue pH 2.5 solution for 30 min. Thereafter, the 14 
staining solution was replaced with the revealing solution for 10 min, and finally the specimens were 15 
washed in dd-H2O for 5 min. Subsequently, the samples were counterstained for 5 min in a dd-H2O solution 16 
containing nuclear fast red (Sigma-Aldrich) diluted to 0.1% w/v and  aluminum sulphate (Sigma-Aldrich) 17 
diluted to 5% w/v and washed in tap water for 5 min to reveal the counterstaining. All the steps were 18 
performed at RT. 19 
 20 
2.3.4 Van Gieson staining 21 
Van Gieson staining shows organized collagen fibers in red, whereas other biomolecules in yellow. The 22 
sections were first counterstained with hematoxylin solution as described in section 2.3.1, then incubated 23 
for 2 min with 1% w/v acid fuchsin (Sigma-Aldrich) in dd-H2O, diluted to 10% in a picric acid saturated 24 
solution (Sigma-Aldrich), and finally washed in dd-H2O.  All the steps were performed at RT. 25 
 26 
2.4 Immunohistochemical (IHC) analyses 27 
The sections were permeabilized using Triton X-100 (Sigma-Aldrich) diluted to 0.2% v/v in 1× PBS for 10 min 28 
and the quenching of endogenous peroxidases was performed through incubation with 0.6% H2O2 (36 29 
volumes) in methanol (Sigma-Aldrich) in the dark for 15 min. To block aspecific binding sites, the samples 30 
were incubated with  goat serum (Vektor Lab, Burlingame, CA, USA) diluted to 5% v/v in 1× PBS at 37°C for 31 
20 min. Therefore, the sections were incubated with the primary antibodies diluted in a solution composed 32 
of bovine serum albumin (BSA, Sigma-Aldrich) diluted to 0.1% in 1× PBS. The slides were placed into a 33 
humidified chamber overnight at 4°C. The following antibodies were used: anti-collagen type I, diluted 34 
1:2000 (ab34710, Abcam, Cambridge, MA, USA); anti-osteocalcin, diluted 1:800 (sc30044, Santa Cruz 35 
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Biotechnology, Santa Cruz, CA, USA); and anti-TGFβ 1, diluted 1:500 (sc-146, Santa Cruz). After each step, 1 
the samples were washed in 1× PBS solution for 10 min. The following day, the specimens were incubated 2 
with goat anti-rabbit or goat anti-mouse biotinylated secondary antibodies (Vektor Lab) diluted 1:200 in 3 
1.5% v/v goat serum solution in 1× PBS for 60 min, and subsequently with streptavidin (Vectastain Elite ABC 4 
Kit Standard, Vektor Lab) for 30 min, according to manufacturer’s instructions. After each step, the samples 5 
were quickly rinsed in 0.01% Triton/1× PBS and washed in 1× PBS solutions for 10 min. To reveal the 6 
reactions, the sections were incubated in the substrate-chromogen solution 0.5 mg/mL 3,3-7 
diaminobenzidine tetrahydrochloride (DAB, Amresco, Solon, OH, USA), in the dark for 5 min. DAB was 8 
activated by adding, immediately before the incubation, 2% v/v of a solution constituted of 1% H2O2 36 9 
volumes and dd-H2O. After 2 washings of 5 min in dd-H20, the specimens were counterstained with 10 
hematoxylin solution for 5 min and washed in tap water for 5 min to reveal the counterstaining. Finally, the 11 
sections were dehydrated and mounted as described in 2.3. All the steps were performed at RT, unless 12 
otherwise specified. The treated histological sections were observed with a Nikon Eclipse Ci microscope 13 
(Nikon Instruments, Amsterdam, The Netherlands) and images were acquired by a digital camera at 200× 14 
original magnification.  15 
 16 
2.5 Histomorphometric analysis 17 
For each biopsy, histological sections were imaged every 30 μm. Micrographs (n = 37, 69, 50, 41 and 34, for 18 
samples at months 4, 4, 6, 7, and 9, respectively) were acquired at 200× original magnification with a 19 
resolution of 2048×1536 pixels to obtain single complete photographic reconstructions of the sections. The 20 
different micrograph numericity depended on the different size of biopsies. The histomorphometric study 21 
was aimed at estimating the surface percentage occupied by SmartBone®, new bone, connective tissue and 22 
other tissues. The different areas in the images, preliminary identified by expert histologists, were manually 23 
selected and analyzed using ImageJ software (version 1.50i; http://imagej.nih.gov), using the function 24 
“Measure” with “Freehand” selection tool. Briefly, in each micrograph the different tissue areas and the 25 
total micrograph area, the latter subtracted from possible empty zones derived by histologic processing, 26 
were measured in pixels by the software, thus allowing the percent areas occupied by SmartBone®, new 27 
bone, connective tissue and other tissues to be calculated without the need to be converted to the scale 28 
bar units. For each patient, the mean percent values of the different areas were obtained as an average 29 
over the number of micrographs analyzed. Finally, the mean percentages of the areas occupied by 30 
SmartBone®, new bone, connective tissue and other tissues, representative of the volumes analyzed, were 31 
given as volumes, considering that the section thickness is much smaller than the section area. 32 
Furthermore, the contribution of SmartBone® particles to new bone formation was evaluated using the 33 
Bone-Particle Conductivity Index (BPCi), defined as 34 
 35 
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BPCi = Lc/Pc 1 
 2 
In which LC is the sum of contact lengths between new bone and SmartBone® particles and PS is the sum of 3 
perimeters of SmartBone® particles, measured via ImageJ software using the function “Measure” with 4 
“Freehand” selection tool. This index ranges from 0, when new bone is not present (only SmartBone® is 5 
present), to an indefinite value, when SmartBone® particles are completely absorbed by the host tissues.  6 
 7 
 8 
3. Results and Discussion 9 
 10 
The ideal scaffold for bone regeneration is required to be highly porous, non-immunogenic, biostable until 11 
the new tissue formation, bioresorbable and osteoconductive. Among the wide number of biomaterials 12 
used for sinus lift in dental surgery, SmartBone® is a new hybrid bone substitute composed by 13 
deproteinized bovine spongy bone, a biodegradable copolymer (PLCL) and gelatin. 14 
This study aimed at investigating the process of new bone formation in 5 patients treated with granular 15 
SmartBone® for sinus augmentation, providing an extensive histologic analysis, which is necessary to 16 
understand the underlying mechanisms driving the biological phenomena at the basis of graft acceptance, 17 
resorption, quality and quantity of new bone formation. Understanding these aspects is fundamental to 18 
accelerate the development of novel materials for bone tissue engineering. 19 
 20 
3.1 Histological analysis 21 
Many authors have reported on the outcomes of different materials used in sinus lift procedures, which 22 
included histological analyses of biopsies performed on reconstructed maxillary bone. These analyses were 23 
mainly carried out to evaluate the material resorption and the presence of new bone tissue using H&E or 24 
Toluidine Blue staining, alone or in combination with Trichromic staining, the latter to reveal collagen fibers 25 
(Galindo-Moreno et al., 2008; Soardi et al., 2011; Spin-Neto et al., 2014). However, these histologic 26 
methods cannot give specific and deepen information on the localization and expression bone ECM 27 
biomolecules, which in our opinion are greatly important to assess the process leading to formation and 28 
maturity of newly formed bone. For these reasons, we performed an extensive histological analysis on sinus 29 
biopsies, consisting in histochemical staining/reaction and IHC reactions performed against specific bone 30 
ECM antigens.  31 
The histological analysis using H&E was firstly performed to understand the timeline of new bone 32 
formation and SmartBone® resorption in the 5 tissue samples, collected at different time points (Figure 1). 33 
At 4 months after implantation, both SmartBone® and new bone could be easily identified, due to absence 34 
and presence of cells inside bone lacunae, respectively (Figure 1 A, B). Differently, starting from month 6, 35 
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SmartBone® was rarely observed, indicating that its resorption had already occurred (Figure 1 C-E). H&E 1 
performed on plain SmartBone® showed that the graft structure maintained the morphological features 2 
typical of bone tissue. In particular, empty bone lacunae, i.e. not occupied by osteocytes, were clearly 3 
observed, indicating complete graft decellularization (Figure 1 F). From our panel of analyses, SmartBone® 4 
resulted unevenly weakly positive to collagen fibers, generic GAGs, glycoproteins, collagen type I and 5 
fibronectin, the latter specifically located around the bone lacunae, while it was negative to TGF-β1. These 6 
results are in line with the non-aggressive deproteinization, as declared by the manufacturer (data not 7 
shown) (Pertici et al., 2014).  8 
A representative biopsy at 4 months (biopsy #1) was chosen to show an extensive characterization of the 9 
tissue (Figure 1A, 2). SmartBone® stained with less intensity than new bone and its bone lacunae did not 10 
contain any osteocytes, thus allowing its easy identification in the histologic sections. In contrast, new bone 11 
areas showed osteocytes housed in the bone lacunae and osteoblasts layering at the periphery of new 12 
bone grown on SmartBone®, which is highly suggestive of good material osteoconductivity. The connective 13 
tissue around bone and SmartBone® areas appeared well-structured, was in contact with SmartBone® and 14 
contained blood vessels, indicating acceptance and integration of the graft material in the recipient site 15 
(Figure 1 A). Areas with some cellular infiltration could be very rarely observed. The co-existence of bovine 16 
graft material and new bone at 4 months is in agreement with the literature, although the data reported at 17 
such an early time point are limited (Wheeler et al., 1997). PAS reaction highlighted good positivity for 18 
glycoproteins in the new bone, mainly along the growth line in contact with SmartBone®, which conversely 19 
appeared negative (Figure 2 A). Generic GAGs were localized mainly around the bone lacunae and, with 20 
less intensity, along the bone lamellae in the new bone, whereas SmartBone® was weakly positive only 21 
around the empty bone lacunae (Figure 2 B). Collagen fibers were well evident in the bone lamellae of new 22 
bone. SmartBone® showed a weak positivity to Van Gieson staining, possibly indicating the presence of 23 
degraded collagen (Figure 2 C). IHC analysis revealed an intense positivity for collagen type I in the new 24 
bone (Figure 2 D). Differently, osteocalcin was detected mainly along bone lamellae at the periphery of the 25 
new bone areas (Figure 2 E). Moreover, TGF-β1 specifically highlighted osteoblasts located along the 26 
margins of the new bone  (Figure 2 F). Briefly, in the 4-month biopsy, both SmartBone® and new bon tissue 27 
were present; new bone grew on SmartBone® and well-structured vascularized connective tissue 28 
surrounded both new bone and SmartBone®. As a proof of cytocompatibility, preliminary in vitro studies 29 
conducted by culturing human mesenchymal stromal cells on SmartBone® cubes for 3 weeks without any 30 
osteogenic supplements showed that the cells were viable, colonized the scaffold and produced generic 31 
GAGs (Figures S1 and S2 – Supplementary). All these data and the almost total absence of inflammatory 32 
cells in the biopsies confirmed that this material is highly biocompatible (Pertici et al., 2015). 33 
From 6 months ahead, SmartBone® started to be completely resorbed and only new bone areas were 34 
visible. These results are different from those using ceramic substitutes, in which resorption at 6 months 35 
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was still partial (Frenken et al., 2010). In the 6-month biopsy, large new bone areas containing osteocytes in 1 
bone lacunae were observed, whereas SmartBone® particles were extremely rare (Figure 1 C). In similar 2 
studies with bone block allografts, the histological analyses at 6 months showed that the graft materials 3 
were still present (Nissan et al., 2011; Spin-Neto et al., 2014), thus indicating that SmartBone® was able to 4 
accelerate new bone formation. In new bone areas, a good positivity for glycoproteins was shown and a 5 
strong presence of generic GAGs was revealed in the ECM surrounding the bone lacunae (Figure 3 A, B). 6 
Collagen fibers were well represented along both the bone lamellae and the bone lacunae (Figure 3 C). 7 
Collagen type I and osteocalcin were detected mainly at the periphery of the bone areas (Figure 3 D,E). In 8 
this biopsy, TGF-β1 was not revealed by IHC analysis (Figure 3 F). 9 
In the 7-month biopsy, well oriented bone lamellae were visible and the presence of some bone scars, 10 
typical of mature bone, could be observed, whereas SmartBone® was very rarely detected (Figure 1 D, 4). 11 
These results are remarkably different from those found in the literature. In these studies, histological 12 
analyses on implanted bovine-derived bone grafts, such as Bio-Oss®, displayed the co-existence of graft 13 
material and new bone in 7-month biopsies, reporting newly formed bone, growth around the graft, with 14 
diverse maturity levels (Yildirim et al., 2000; Froum et al., 2008). In contrast, the new bone found in our 15 
samples appeared highly mature. The glycoproteins were intensely expressed along bone lamellae and in 16 
the bone scars (Figure 4 A). Good positivity for generic GAGs was revealed around bone lacunae, whereas it 17 
was weak along bone lamellae (Figure 4 B). Van Gieson staining highlighted well oriented collagen fibers in 18 
the bone lamellae (Figure 4 C). High levels of expression for collagen type I and osteocalcin were detected 19 
in the bone lamellae (Figure 4 D, E). Finally, TGF- β1 was strongly expressed in the osteoblasts at the 20 
margins of new bone (Figure 4 F). 21 
In the 9-month biopsy, new bone areas containing osteocytes in the bone lacunae and many bone scar lines 22 
were imaged, while SmartBone® was absent (Figure 1 E). Glycoproteins were well expressed mainly in the 23 
bone scars (Figure 5 A). Good positivity for generic GAGs was shown around the bone lacunae (Figure 5 B). 24 
Well oriented collagen fibers were detected and collagen type I was observed along the bone lamellae 25 
(Figure 5 C, D). In a similar fashion, osteocalcin was well expressed in the bone areas (Figure 5 E). Weak 26 
TGF- β1 expression was observed in the cells located along the margin of the bone tissue (Figure 5 F). 27 
In all the biopsies, the presence of the most important bone ECM biomolecules, such as  glycoproteins, 28 
generic GAGs and collagen fibers, was assessed. The progression of bone biomolecule expression along the 29 
time, as well as the appearance of specific morphologic features of mature bone, like oriented bone 30 
lamellae and bone scars, indicated that around 6 months after implantation, the newly formed bone tissue 31 
was mature. Month 6 seemed to be a turning point, as Smartbone® was also almost fully resorbed. The 32 
presence of many osteoblasts along the margins of new bone, observed in all the biopsies, indicated that 33 
new bone formation process is well underway.  In a comparative study between anorganic bovine matrix 34 
(Bio-Oss®) and a mineralized cancellous bone allograft (Puros®), a significant new bone amount was formed 35 
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in patients implanted with Puros®, which may suggest a fundamental role played by the co-existence of 1 
both mineral and organic bone ECM in bone regeneration (Froum et al., 2006). SmartBone® is a hybrid 2 
scaffold designed to have an improved performance with respect to those of other anorganic xenografts, 3 
by using deproteinized bovine bone combined with biocompatible and bioresorbable biopolymers, such as 4 
PLCL and gelatin. The graft part of SmartBone® is harvested from bovine bone and treated via acid attack at 5 
low temperature (Pertici, 2010; Pertici et al., 2014). This process is performed to mildly remove the organic 6 
matrix from the xenograft, thus reaching non-immunogenicity while preserving the chemical structure of 7 
the mineral phase. As a consequence, the final scaffold can undergo complete remodeling, as also 8 
corroborated by our observations in the 9-month biopsy. As soon after surgery, the added biopolymers are 9 
specifically designed to improve the volumetric stability of the granular graft. Gelatin increases the graft 10 
wettability, which ultimately leads to the formation of a paste, easy to manage, due to rapid and deep 11 
blood absorption, which enables the recruitment of neighboring cells into the scaffold, thus stimulating 12 
bone cell adhesion and proliferation. Other porous biodegradable spongy scaffolds based on poly(L-lactic 13 
acid) (PLA) and gelatin were proven to be blood compatible, support osteoblast adhesion and allow the 14 
formation of osteogenic niches (Lazzeri et al., 2007; Danti et al. 2007; Danti et al. 2012). The addition of 15 
biopolymers and gelatin to deproteinized bovine graft is hypothesized to be a key feature to activate the 16 
processes of new bone formation and graft resorption in such a short time frame.  17 
 18 
3.2 Histomorphometric analysis 19 
Histomorphometric analysis is a software-aided tool for the quantitative evaluation of histologic specimens, 20 
which enables a robust understanding of bone formation versus graft resorption and permits comparisons 21 
among samples (Egan et al., 2012). In a meta-analysis review, Klijn and coworkers carried out a systematic 22 
evaluation of the effects played by material, biopsy time, technique (block or particulated grafting), 23 
collagen membrane (presence or absence), and implant strategy (immediate or delayed), on the amount of 24 
total bone volume detected by histomorphometric analysis (Klijn et al. 2010). This study showed that 25 
grafting type, time of biopsy collection and strategy of implant placement were all significant variables on 26 
the histomorphometric outcomes for many biomaterials. We thus evaluated the histomorphometric results 27 
obtained with SmartBone® , comparing them to those reported for similar materials (deproteinized bovine 28 
matrices). We also compared similar/higher histomorphometric results of different materials to those 29 
obtained using SmartBone®. In these comparisons, we considered these specific variables: biopsy times, 30 
particulate grafting, presence of a collagen membrane and delayed implant. 31 
The results of volume percentages of new bone, SmartBone®, connective and other tissues obtained in our 32 
samples via histomorphometric analysis are reported in Figure 6. In the two biopsies at 4 months after 33 
SmartBone® implant, the new bone volume averagely accounted for 43.9% (40.3%-47.5% range) of the 34 
total sample volume. At that time point, particulate SmartBone® was already massively resorbed, being 35 
12 
 
detected on average at 12% (10.5%-12.5% range). Connective tissue still averagely covered 37.2% (37.0%-1 
37.4% range) of the total volume (Figure 6 A,B). The literature on 4-month biopsies is very limited, as they 2 
are usually carried out at later time points. Wheeler and colleagues reported on 4 sinus biopsies obtained 3 
at 4 months after implantation of Interpore® 200, an anorganic deproteinized bovine bone grafts, in which 4 
the bone volume accounted for 12.02% (Wheeler at al., 1996). Another study on 3 sinuses performed at 4 5 
months using particulate autograft (namely, the gold standard material), but in absence of collagen 6 
membrane, showed 40.94% of total bone volume, which may be comparable to the results obtained using 7 
SmartBone® (Tadjoedin et al., 2000). A similar outcome was reported using anorganic deproteinized bovine 8 
bone particles (Bio-Oss®) mixed with autologous bone graft in 2 sinuses at 12 months post implantation 9 
(45.6% bone volume) (Artzi et al., 2005). These comparisons, even though conducted on limited biopsy 10 
numbers, are strongly suggestive of the highest SmartBone® performance with respect to those of 11 
anorganic bovine bone substitutes. The rate of new bone formation appears to be induced by biological 12 
phenomena occurring at early times post implantation, thus highlighting that the hybrid composition really 13 
makes a difference. 14 
At 6 and 7 months, Smartbone® particles were rarely present (0.5%), new bone covered almost completely 15 
the sample areas with volume percentages of 80.8% and 79.3%, respectively, and connective tissue was 16 
reduced to 18.7% and 20.2%, respectively (Figure 6 C, D). Such high bone volumes in sinus augmentation, 17 
specifically 70.0% and 69.7%, have solely been shown using particulate autografts as maxillary fillers at 5 18 
months, under the same variables mentioned above (Barone et al. 2005; Crespi et al., 2007). In fact, results 19 
at 6 months using anorganic deproteinized bovine bone (Bio-Oss®) showed only 13.5% and 18.30% new 20 
bone volumes (Yildirim et al., 2000; Lee et al., 2006), and 22.3% just after the 7th month (Froum et al. 2008). 21 
At 9 months post SmartBone® implant, the new bone volume accounted for 67.4%, connective tissue for 22 
25.6% and other tissues for 7.0%. SmartBone® was never detected in this biopsy (0%) (Figure 6 E). At the 23 
same time point and variable conditions, implanted Bio-Oss® was reported to have induced just 16.5% 24 
bone volume (Yildirim et al., 2000). 25 
To improve the comprehension of the mechanisms leading to new bone formation and SmartBone® 26 
resorption, we evaluated an osteoconductivity index, specifically the BPCi. This index measures the contact 27 
between the new bone and material particles, thus being a tool to assess osteoconductivity. It has to be 28 
underlined that, in case of a resorbable particulate, this index is affected by two competitive kinetics, the 29 
material resorption velocity and the bone growth velocity. Moreover, for its constitutive definition, the 30 
BPCi ranges from 0 (only material particles) to indefinite (only new bone). As such, it can be measured only 31 
when the material particles are present. In the 4-month biopsies, the BPCi resulted to range in 19.1%-32 
25.3%, indicating that averagely 22.2% of the SmartBone® areas were in contact with newly formed bone. 33 
In the biopsies at later time points (6 and 7 months), the quantity of SmartBone was so small (0.5% in 34 
volume) that BPCi was very difficult to evaluate. At 9 month, SmartBone® was no more detectable, making 35 
13 
 
BPCi indefinite. From these preliminary evaluations, also corroborated by the histological outcomes, it can 1 
be stated that SmarBone® owns good osteoconductivity, although shorter time points (< 4 months) are 2 
necessary to define the role and entity of osteoconductivity on the process of new bone formation driven 3 
by SmartBone®.  4 
SmartBone® is an innovative bone substitute composed by bovine spongy bone, which is deproteinized via 5 
a mild acid attack process to preserve the graft structure, and ultimately added with PLCL as a 6 
biodegradable copolymer and gelatin to improve its volumetric stability and wettability at the onset of 7 
implantation. Gelatin was also chosen to offer RGD-sequences to cells in order to better support their 8 
adhesion and spreading. This hybrid formulation leads to the formation of a paste, due to rapid and deep 9 
blood absorption, which recruits the neighboring cells to get into the scaffold. This peculiarity seems to be a 10 
key feature to activate very soon the processes of new bone formation and graft resorption.  11 
 12 
4. Conclusions 13 
 14 
Upon SmartBone® implantation for sinus lift, in the 4-month biopsies, new bone was largely present 15 
(43.9%) and partially in contact with the residual SmartBone® (12%), which was already partially resorbed 16 
(BPCi = 0.22). The new bone volume was comparable to the total bone volume measured at 4 months using 17 
bone autografts, which is the gold standard material for this procedure. Other anorganic xenografts scored 18 
much lower values at the same time point, or needed, even if mixed with bone autografts, much longer 19 
times to reach similar results. At 6 months, the residual SmartBone® was very small (0.5%) and new bone 20 
was massively present (80.8%), a result comparable only to some outcomes obtained using particulate 21 
bone autografts. At 7 and 9 months, SmartBone® was 0.5% and 0%, respectively, and well-oriented 22 
lamellae and bone scars, typical of mature bone, were observed. Bone matrix biomolecules and active 23 
osteoblasts, positive for TGF-β1, were very often visible. The absence of inflammatory cells confirmed 24 
SmartBone® biocompatibility and non-immunogenicity. Even though these data are obtained on a limited 25 
number of patients and shorter time points would be necessary to completely understand the biological 26 
phenomena occurring in the very early stages of new bone formation, the obtained outcomes showed that 27 
SmartBone® is osteoconductive, promotes fast bone regeneration, leading to mature bone formation in 28 
about 7 months.  29 
 30 
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Figure legends 1 
 2 
Figure 1.  H&E staining of maxillary bone biopsies and pristine SmartBone® material. (A) Biopsy #1 at 4 3 
months. (B) Biopsy #2 at 4 months. (C) Biopsy at 6 months. (D) Biopsy at 7 months. (E) Biopsy at 9 months. 4 
(F) Plain SmartBone® material. (A-F) Original magnification ×200. NB = new bone; SB = SmartBone®; CT = 5 
connective tissue; gl = growth line; V = blood vessels; black arrow = bone lacunae; red arrow = bone scar; 6 
black arrowhead = osteoblasts; red arrowheads = bone lamellae. 7 
         8 
Figure 2.  Histological analyses of a representative biopsy at 4 months (biopsy #1). (A) PAS reaction reveals 9 
the presence of glycoproteins in magenta. (B) Alcian Blue staining at pH 2.5 shows generic GAGs in cyan. (C) 10 
Van Gieson staining reveals collagen fibers in new bone areas in red. Non-collagenic elements are stained in 11 
yellow. Cell nuclei are stained in black. (D) IHC analysis shows collagen type I localization. (E) IHC analysis 12 
reveals osteocalcin. (F) TGF-β1 is detected via IHC. (A-E) Original magnification ×200. (F) Original 13 
magnification ×400. (A-F) NB = new bone; SB = SmartBone®; CT = connective tissue; gl = growth line; black 14 
arrow = bone lacunae; black arrowheads = osteoblasts; red arrowheads = bone lamellae. 15 
 16 
Figure 3.  Histological analyses on the biopsy at 6 months. (A) PAS reaction shows the glycoproteins in 17 
magenta. (B) Alcian Blue at pH 2.5 reveals generic GAGs in cyan. (C) Van Gieson staining shows collagen 18 
fibers in red. Non-collagenic elements are stained in yellow. Cell nuclei are in black. (D) IHC analysis reveals 19 
collagen I. (E) IHC analysis shows osteocalcin localization. (F) IHC reaction is negative for TGF-β1. (A-E) 20 
Original magnification ×200. (F) Original magnification ×400. (A-F) Black arrow = bone lacunae; red 21 
arrowheads = bone lamellae. 22 
 23 
Figure 4.  Histological analyses on the biopsy at 7 months. (A) PAS reaction shows glycoproteins in 24 
magenta; bone scars are visible and intensely positive. (B)  Alcian Blue at pH 2.5 shows generic GAGs in 25 
cyan. (C) Van Gieson staining shows collagen fibers in red. Cell nuclei are stained in black. (D) IHC analysis 26 
detected collagen type I. (E) IHC analysis shows osteocalcin. (F) TGF-β1 is localized via IHC analysis. (A-E) 27 
Original magnification ×200. (F) Original magnification ×400. (A-F) Black arrow = bone lacunae; red arrows = 28 
bone scar; black arrowheads = osteoblasts; red arrowheads = bone lamellae. 29 
 30 
Figure 5.  Histological analyses on the biopsy at 9 months. (A) PAS reaction shows glycoproteins in 31 
magenta. (B) Alcian Blue at pH 2.5 shows generic GAGs in cyan. (C) Van Gieson staining reveals collagen 32 
fibers in red. Non-collagenic areas are stained in yellow; cell nuclei are stained in black. (D) IHC analysis 33 
detected collagen type I. (E) IHC analysis shows osteocalcin. (F) IHC reveals TGF-β1. (A-E) Original 34 
20 
 
magnification ×200. (F) Original magnification ×400. (A-F) Black arrow = bone lacunae; red arrows = scar 1 
bone; black arrowheads = osteoblasts; red arrowheads = bone lamellae. 2 
 3 
Figure 6. Histomorphometric analysis showing volume percentages of new bone, SmartBone®, connective 4 
tissue, and other tissues in the biopsies taken at the following times post SmartBone® implantation: (A) 4 5 
months (Biopsy #1); (B) 4 months (Biopsy #2); (C) 6 months; (D) 7 months; (E) 9 months. The results show 6 
the timeline of SmartBone® resorption (13.5% to 0%) and new bone formation (ranging in 40.3%-80.8%).  7 
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